In order to determine the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo, a series of episomal plasmid -based ''splice -activated gene expression'' ( pSAGE ) vectors was generated, which contain minigene cassettes composed of various combinations of the three alternatively spliced exons present in the differentially expressed adhesion protein CD44R1 ( v8, v9, and v10 ) with or without their corresponding intronic sequences, positioned in -frame between the CD44 leader sequence and a ''leaderless'' human liver / bone / kidney alkaline phosphatase ( ALP ) cDNA. Because both the v8 -v9 and v9 -v10 introns contain multiple in -frame stop codons, the expression and enzymatic activity of ALP are dependent upon the accurate removal of intronic sequences from the pre -mRNA transcripts encoded by these constructs. The various pSAGE constructs were introduced into CD44H -positive ( T24 ) and CD44R1 -positive ( PC3 ) target cells by electroporation and transfectants selected in hygromycin B. ALP expression was determined by staining with the ALP substrate, BCIP / INT, and the transfected cells tested for their sensitivity to the inactive prodrug, etoposide phosphate. ALP -mediated dephosphorylation of etoposide phosphate generates the potent topoisomerase II inhibitor etoposide. The data obtained indicate that whereas the v8 -v9 intron is spliced in both CD44H -and CD44R1 -positive cells, the v9 -v10 intron is efficiently and accurately removed only in CD44R1 -positive cells. Furthermore, only CD44R1 -positive cells were sensitized to etoposide phosphate when transfected with the v9 -v10.ALP construct. These data emphasize the potential usefulness of alternative splicing as a novel means of targeting gene expression to tumor cells in vivo. Cancer Gene Therapy ( 2002 ) 9, 133 -141 DOI: 10.1038 / sj / cgt / 7700427 Keywords: CD44; alternative splicing; cancer gene therapy G ene therapy shows great promise as a modality in the treatment of cancer.
G ene therapy shows great promise as a modality in the treatment of cancer. 1 As the result of progress made in recent years, there is now no shortage of candidate genes which, if expressed at a high -enough level, can either directly kill tumor cells or sensitize them to the cytotoxic effects of ionizing radiation and/ or chemotherapeutic agents. 2 A major outstanding challenge is to develop a safe, effective, and practical means of targeting such genes to tumor cells in vivo while minimizing as much as possible the damage inflicted on normal tissues. 3 In this regard, promising results have been obtained using engineered viral vectors that exhibit restricted cellular tropism. 4 Similarly, a number of promoter /enhancer elements have been identified, which can be used to control gene expression in particular cell types or tissues. 5, 6 Although little explored, there are additional ways in which gene expression could potentially be targeted to particular cell types in vivo. Specifically, because tumor cells and normal cells differ in their ability to alternatively splice certain pre -mRNA transcripts, 7 linking the expression of a therapeutic gene to a tumor-specific mRNA processing event may constitute a potentially powerful means through which differences between normal and malignant cells can be exploited to target the tumor population.
A critical step in eukaryotic gene expression involves the removal of intronic sequences from pre -mRNA transcripts in the nucleus prior to their transport to the cytoplasm where translation occurs. 8 This process is termed ''splicing.'' It is now appreciated that a large proportion of cellular genes encode primary transcripts in which exonic sequences can be spliced in different ways to generate multiple mRNA species that encode protein isoforms with unique structures and functions. 9 This latter process, termed ''alternative splicing,'' enhances the coding potential of the genome without the need to resort to gene duplication events. 10 Alternative splicing is a highly regulated process with distinct patterns of splicing occurring during cellular differentiation, in different tissues, or in response to particular extracellular signals. 9, 10 Importantly, alterations in alternative splicing are commonly observed in malignancy. 11, 12 In this study, we explore the possibility that differences in the ability of normal and malignant cells to alternatively splice certain pre -mRNA transcripts can be exploited as a means of targeting gene expression to the latter population.
The basic approach is to physically link a gene of interest to a minigene construct that incorporates two or more exons ( along with their respective introns ) derived from a gene that is alternatively spliced. Initial ''proof of principle'' studies have focused on the adhesion protein, CD44. CD44 is a broadly distributed cell surface glycoprotein that functions as a receptor for the extracellular matrix component, hyaluronan. 13 Importantly, although the 80 -to 90 -kDa CD44 isoform designated CD44H is present on most resting and nontransformed cells, alternative splicing events involving a contiguous series of 10 exons ( v1 -v10 ) present within the single-copy CD44 gene generate a large number of higher -molecular-weight isoforms that are differentially expressed on various activated and /or malignant cell types. 7 Significantly, correlations have been noted between the expression of certain of these isoforms and both metastatic propensity and prognosis. We and others have shown, for example, that colorectal carcinomas expressing high levels of CD44R1, a CD44 isoform containing the alternatively spliced exons v8, v9, and v10, fair far worse with respect to 5 -year survival than those that express predominantly the common 90 -kDa CD44 isoform ( CD44H ) that lacks sequences encoded by the alternatively spliced exons. 14 Similar results have been obtained for variety of other hemopoietic and nonhemopoietic malignancies. 15 -17 In initial experiments designed to test the potential of alternative splicing as a regulator of therapeutic gene expression, a series of episomal plasmid -based ''spliceactivated gene expression'' ( pSAGE ) vectors was generated, which contain a minigene cassette composed of various combinations of the three alternatively spliced exons present in CD44R1 ( v8, v9, and v10 ) with or without their corresponding intronic sequences, positioned in -frame between the CD44 leader sequence and a ''leaderless'' human liver /bone /kidney alkaline phosphatase ( ALP ) cDNA. ALP can activate the prodrug etoposide phosphate ( Etopophos) generating the potent topoisomerase II inhibitor, etoposide. 18 -20 Because both the v8-v9 and v9 -v10 introns contain multiple in -frame stop codons, ALP expression and subsequent sensitivity to etoposide phosphate are dependent upon the accurate removal of intronic sequences from the pre -mRNA transcripts encoded by these various constructs. The results obtained indicate that although the v8 -v9 intron is spliced in both CD44H -and CD44R1-positive cells, accurate removal of the v9 -v10 intron only occurs in CD44R1-positive cells. Thus, constructs in which expression of ALP is dependent upon removal of the v9-v10 intron can be used to selectively sensitize CD44R1 -positive cells to the cytotoxic effects of etoposide phosphate while leaving CD44H -positive cells unaffected. These data emphasize the potential usefulness of splice -activated regulatory elements as a means of improving the safety and efficacy of gene therapy in the treatment of cancer.
Materials and methods

Cell lines
The prostate adenocarcinoma cell line, PC3, 21, 22 and the urinary bladder transitional carcinoma cell line, T24, 23, 24 were obtained from the American Type Culture Collection ( Rockville, MD ). Both cell lines were cultured in Dulbecco's minimum essential medium (DMEM ) ( Life Technologies, Grand Island, NY ) supplemented with 10% fetal bovine serum (FCS; Sigma, St. Louis, MO ), 1000 U /mL penicillin -streptomycin ( Life Technologies ), and 0.3 mg / mL L -glutamine ( Mediatech -Cellgro, Herndon, VA ) ( DMEM + 10% FCS ) at 378C in an atmosphere containing 5% CO 2 .
Monoclonal antibodies ( mAbs )
The generation and characterization of the anti -CD44 mAb 4A4 and the CD44 exon v10-specific mAb 2G1 have been described in detail previously. 25 -28 FACS analysis 
Western blot analysis
T24 and PC3 cells were harvested by brief incubation in PBS containing 2.5 mM EDTA, washed extensively with PBS, and resuspended at 2Â10 7 cells /mL in PBS containing 1% ( vol /vol ) NP40, 5 mM EDTA, and 10 mM phenylmethylsulphonyl fluoride. After incubation on ice for 15 minutes, the lysates were microfuged for 5 minutes to pellet nuclei and other cellular debris, and aliquots stored at À 708C until required. Lysates derived from COS7 cells transfected with various CD44 cDNA (CD44H, CD44R1, and CD44R2 ) in the expression vector CDM8 were used as controls. 29 Samples were rapidly thawed, added to an equal volume of nonreducing sample buffer [ 125 mM Tris, 20% (vol / vol ) glycerol, 4.6% (wt /vol ) SDS, pH 6.8] and incubated for 5 minutes at 1008C. Total cellular proteins were separated by SDS -PAGE and transferred onto nitrocellulose membranes ( Bio -Rad, Hercules, CA ). Filters were blocked with PBS containing 5% ( wt /vol ) milk protein by overnight incubation at 48C. After extensive washing in HBSS, filters were incubated with mAb 4A4 tissue culture supernatant for 4 hours at room temperature, washed in HBSS for 30 minutes, and then incubated for a further 1 hour with a 1:100 dilution of horseradish peroxidase -conjugated goat antimouse IgG ( Sigma ) in DMEM + 10% FCS. After extensive washing in HBSS, the reaction was developed in PBS containing 0.06% 3 -3 0 diaminobenzidine ( Sigma ) and 0.012% (vol /vol ) hydrogen peroxide ( Sigma ).
Introduction and expression of ALP in T24 and PC3 cells
A XhoI-BamHI fragment containing the full -length human liver/bone /kidney ALP cDNA was isolated from the plasmid pUC19.ALP and cloned into the XhoI-BamHI sites of the episomal EBV-based expression vector pCEP4 ( Invitrogen, Carlsbad, CA ) generating plasmid pCE-P4.ALP. Control pCEP4 and pCEP4.ALP plasmid DNA were introduced into T24 and PC3 cells by electroporation. Briefly, log phase T24 and PC3 cells were harvested by gentle trypsinization, resuspended in DMEM +10% FCS, and pelleted by centrifugation. Cells were washed once in PBS and resuspended at approximately 1Â10 7 cells /mL in PBS. Aliquots of 0.5 mL of each cell suspension were mixed with 20 g of plasmid DNA and 400 L transferred to a 2 -mm gap electroporation cuvette ( BTX, San Diego, CA ). Samples were electroporated at 280 V, capacitance setting 300 F, resistance R3 ( 48 ) using a BTX600 electroporator ( BTX ). The time constants obtained generally ranged around 3.1 mS. The contents of each electroporation cuvette Figure 1 Construction of pSAGE vectors. The major steps in the construction of the pSAGE.v8 -v9.ALP vector are illustrated.
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Splice -activated gene expression GM Hayes et al were immediately resuspended in 30 mL of DMEM + 10% FCS and plated in a 15 -cm Integrid tissue culture dish ( Falcon, Franklin Lakes, NJ ). The next day, hygromycin B ( Sigma ) was added at a final concentration of 200 g/mL and the transfectants selected for 14 days. To determine ALP expression, transfected T24 and PC3 cells growing on glass coverslips were fixed for 20 seconds in ethanol, briefly airdried, overlaid with BCIP /INT (Moss Scientific, Pasadena, MD ), and incubated for 10 -30 minutes at room temperature. Coverslips were then washed in H 2 O, counterstained with hematoxylin, and mounted in aqueous mounting medium ( Gel / Mount; Biomeda, Foster City, CA ).
Short -term cytotoxic activity of etoposide and Etopophos
Although phosphorylation of etoposide increases solubility in aqueous solutions, the resultant prodrug (etoposide phosphate or Etopophos) has little cytotoxic activity in vitro. However, dephosphorylation mediated by ALP generates the active agent, etoposide, which is a potent topoisomerase II inhibitor. In order to determine whether expression of ALP sensitizes tumor cells to killing by etoposide phosphate, the cytotoxic activity of both the prodrug and active agent, etoposide, was determined using a short -term apoptosis assay in which the binding of FITCconjugated Annexin was used as a measure of cell death. Briefly, 5Â10
4 control pCEP4 transfected PC3 or T24 cells or PC3 and T24 cells transfected with pCEP4.ALP ( see above ) were added to the wells of a six -well plate and incubated overnight at 378C. The next day, the culture medium was removed and the cells washed twice with PBS. The adherent cell monolayers were then overlayed with 1 mL of DMEM or 1 mL of DMEM containing 10 nM / mL Etopophos (Bristol Laboratories, Princeton, NJ ) or 10 nM / mL etoposide ( Sigma ) and incubated for a further 24 hours. The supernatant containing any nonadherent cells was removed and the adherent cells remaining in each well harvested by gentle trypsinization and pooled with the nonadherent population. The harvested cells were washed twice with PBS and resuspended in 100 L of binding buffer ( 10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). To each sample, 5 L of FITC -Annexin (Pharmingen, San Diego, CA ) and 10 L of a PI stock solution (50 g /mL in PBS ) (Sigma) were added and incubated at room temperature, protected from light, for 15 minutes. An additional 400 L of binding buffer was added and the samples immediately analyzed by flow cytometry using a FACSCalibur machine.
Construction of pSAGE vectors
The various stages involved in the construction of the pSAGE vector series are illustrated in Figure 1 . Briefly, the extracellular domain of CD44R1 was amplified from clone pCDM8.CD44 cl 2. The resultant approximately 1200-bp fragment was digested with XbaI and cloned into the XbaI site of pBluescript KS + (pBS.KS + ). A clone in which the insert is present in the appropriate orientation was selected and plasmid DNA was digested with ClaI and XhoI to remove the coding region of the mature CD44R1 protein, leaving a vector that contains only the CD44 leader sequence ( pBS.CD44L ). A fragment containing CD44 exon v8 and v9 and the corresponding v8-v9 intron was amplified from genomic DNA by PCR using the following primer pair: 5
The same basic approach using primer pair: 5 0 -CCATC-GATGGGCA GTAATTCTCAGACG -3 0 and 5 0 -CCGCTC-GAGGCGATTGACATTAGAGTTGG -3 0 was employed to generate a vector designated pSAGE.v9-10.ALP that contains the CD44 leader sequence, exon v9 and v10 and the corresponding v9 -v10 intron together with leaderless ALP. Control pSAGE.v8 /9.ALP and pSAGE.v9/ 10.ALP cDNA vectors that lack intronic sequences were similarly generated using the CD44R1 cDNA clone pCDM8.CD44R1 cl 2.3 as a template in the initial PCR reactions. pSAGE vectors were introduced into T24 and PC3 cells by electroporation and the transfectants selected in hygromycin B as described above. Once again, staining with the BCIP / INT substrate was used to determine ALP expression.
Clonogenic survival assay
A clonogenic survival assay was employed to determine the sensitivity of control and pSAGE transfected T24 and PC3 cells to etoposide and etoposide phosphate. Briefly, 3Â10 3 T24 and PC3 cells were added to the wells of a 24-well plate. The plates were incubated overnight at 378C after which the culture medium was removed and the adherent cell monolayers washed twice with PBS. To each cell line was added either etoposide ( 10 nM final in DMEM ) ( Sigma ), Etopophos ( 10 nM final in DMEM ) ( Bristol Laboratories ), or control DMEM, and the plates incubated for a further 24 hours. The culture media was then removed, the cells harvested with trypsin, and the contents of each well plated in a 100 -mm tissue culture dish in a final volume of 10 mL of DMEM + 10% FCS. Dishes were incubated undisturbed for 7 days after which time they were washed once with PBS and then stained with methylene blue (2.5% wt /vol in methanol ) (Fisher, Pittsburgh, PA ). The total number of colonies per plate was determined.
Results
Expression of CD44R1 on T24 and PC3 cells
FACS analysis was used to screen tumor cell lines for expression of the alternatively spliced CD44 isoform 
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Splice -activated gene expression GM Hayes et al CD44R1. As shown in Figure 2 , both T24 and PC3 cells express high levels of CD44 as determined by reactivity with mAb 4A4, an antibody that recognizes a common determinant shared by all CD44 isoforms. In contrast, whereas T24 cells show little reactivity with the CD44 exon v10 -specific mAb 2G1, significant staining of PC3 cells is evident. Given that T24 cells express a higher overall level of CD44, it would seem that a greater proportion of the CD44 molecules expressed by PC3 contains the alternatively spliced exon v10. Western blot analysis confirmed this conclusion and demonstrated significant expression of a 135 -kDa CD44 species corresponding in size to CD44R1 in PC3 cells but not T24 cells ( Fig 3 ) . T24 cells do express low levels of a higher-molecular -weight CD44 species that corresponds in size to CD44R2 (an alternatively spliced isoform that contains exon v10, but not exons v8 and v9 ) as well as low levels of an approximately 200-kDa species that corresponds to chondroitin sulfate -modified CD44H ( Fig 3 ) .
Introduction and expression of ALP in T24 and PC3
In order to determine whether expression of ALP sensitizes cells to killing by the prodrug, etoposide phosphate ( Etopophos), T24 and PC3 cells were transfected with the control plasmid pCEP4, or a pCEP4 vector encoding the full -length ALP cDNA ( pCEP4.ALP ). Transfected cells were selected in hygromycin B and ALP expression determined by staining with the ALP substrate, BCIP / INT. As shown in Figure 4 , A and B, although pCEP4 transfected PC3 and T24 cells lack detectable ALP expression, high levels of ALP are evident in both cell lines upon transfection with pCEP4.ALP.
Activation of the cytotoxic activity of etoposide phosphate by ALP
Control and ALP expressing PC3 and T24 cells were next tested for sensitivity to both etoposide and its inactive prodrug, etoposide phosphate ( Etopophos), using a shortterm apoptosis assay. As shown in Figure 4C , whereas control and ALP -expressing PC3 cells are both equally sensitive to etoposide, only the ALP -expressing cells undergo apoptosis in response to exposure to etoposide phosphate as determined by FITC -Annexin binding and PI uptake. Although T24 appears somewhat more resistant to the proapoptotic effects of etoposide during the brief period of observation, it is clear once again that expression of ALP also sensitizes these cells to the etoposide phosphate (Fig 4D ) .
Splicing of v8 -v9.ALP and v9 -v10.ALP minigene constructs in T24 and PC3 cells T24 and PC3 cells were transfected with minigene constructs in which expression of a chimeric ALP protein containing CD44 exons v8 and v9 or v9 and v10 required accurate and complete removal respectively of the v8-v9 or v9 -v10 introns. Equivalent pSAGE constructs generated using cDNA sequences that lack intronic sequences were used as controls and confirmed that chimeric ALP proteins incorporating exons v8 and v9 or v9 and v10 retain enzymatic activity when expressed in T24 or PC3 cells as determined by BCIP / INT staining ( Figs 5, A and B ) . Similarly, both T24 and PC3 cells exhibit strong ALP activity when transfected with the v8 -v9.ALP genomic construct, suggesting that the v8 -v9 intron is constitutively spliced irrespective of whether the cell lines involved express CD44H or CD44R1 ( Fig 5, A and B ) . In contrast, the v9-v10 intron appears to be differentially spliced in CD44H -and CD44R1 -positive cells. Thus, whereas ALP activity can be readily detected in PC3 cells transfected with the v9-v10.ALP construct (Fig 5A ) , no such activity is evident in similarly transfected T24 cells ( Fig 5B ) .
Sensitivity of T24 and PC3 cells transfected with v8 -v9.ALP and v9 -v10.ALP minigene constructs to the prodrug, etoposide phosphate T24 and PC3 cells transfected with the full -length ALP cDNA or the various genomic and cDNA pSAGE constructs were tested for their sensitivity to etoposide and etoposide phosphate ( Etopophos) using a standard clonogenic survival assay. As shown in Figure 6 , all of the transfected cell lines were killed by etoposide irrespective of their expression of ALP. In contrast, only ALP -positive cells were killed by exposure to etoposide phosphate. Thus, the differential ability of CD44R1 -positive PC3 cells to splice the v9-v10 intron ( Fig 5) caused these cells to be sensitized to etoposide phosphate upon transfection with the v9 -v10.ALP pSAGE vector (Fig 6A ) , whereas CD44H -positive T24 cells remain resistant (Fig 6B) as they lack the ability to accurately remove the v9 -v10 intronic sequence and do not therefore express ALP activity (Fig 5 ) . Using a sensitive RT-PCR technique, it was demonstrated that whereas the v8 -v9 intron is efficiently removed in all cell types examined, in cells that lack expression of v10 -containing CD44 isoforms ( e.g., T24 ), alternative 5 0 and 3 0 splice sites located within the v9 -v10 intron are preferentially used, resulting in intron retention and inappropriate termination of translation ( data not shown). No appropriate splicing between exon v9 and v10 could be detected in T24 cells. Appropriate splicing of the v9 -v10 intron only occurred in cells that express exon v10 -containing CD44 isoforms (e.g., PC3 ).
Discussion
The safety and efficacy of gene therapy -based approaches to the treatment of cancer would be greatly improved if simple and efficient means could be developed to target the expression of therapeutic genes to the malignant cell population in vivo. 3, 6 To this end, several groups have generated genetically engineered viral vectors that can infect only a particular subset of cells. 4 Promoter / enhancer elements that can drive gene expression in certain normal and /or malignant cell types, but not others, have also been identified and have proven useful in some circumstances. 5, 6 In the present study, we demonstrate that the differential alternative splicing of pre -mRNA transcripts can be exploited as a novel means of targeting gene expression to tumor cells exhibiting a particular phenotype. Specifically, we have shown that when included in a minigene construct, the intron separating the alternatively spliced CD44 exons v9 and v10 is accurately removed only in cells that express CD44R1, a CD44 isoform that contains sequences encoded by exons v8, v9, and v10. 29 In cells that express CD44H, the CD44 isoform most often found on normal nontransformed cells, alternative splice donor and acceptor sites present within the v9 -v10 intron are preferentially used, resulting in portions of intronic sequence being retained within the processed mRNA transcript (Hayes et al, manuscript submitted ). Because the retained intronic sequences contain inframe stop codons, translation is prematurely terminated and any amino acids encoded by downstream sequences are not included the final protein product. Thus, one can readily design vectors in which expression of a chimeric therapeutic gene incorporating CD44 exons v9 and v10 can be targeted to CD44R1 -positive cells as only they possess the machinery necessary to completely splice the v9 -v10 intron.
Previously, it has been shown that mAb-ALP immunoconjugates can enhance the antitumor activity of phosphorylated mitomycin C and etoposide derivatives both in vitro and in vivo. 18, 19 Although effective in model systems, antibody -directed enzyme prodrug therapy (ADEPT )-based therapeutic approaches have generally proven less successful in the clinic 30 except in context of certain hemopoietic malignancies. 31 Problems include the difficulties inherent in achieving sufficient antibody concentrations in the poorly perfused areas of solid tumors that are perhaps most resistant to conventional therapies. More importantly, perhaps, few target antigens have been identified, which are both noninternalized and differentially expressed at sufficient density on the surface of tumor cells. Finally, tumor cell heterogeneity and clonal instability may permit the rapid expansion of antigen loss variants in treated individuals. In contrast, with appropriate vector design, it may be feasible to achieve high -level expression of enzymes capable of activating prodrugs within the tumor microenvironment using gene therapy approaches, and the bystander killing that may result from the activation of readily diffusible prodrugs may obviate the necessity that every tumor cell be transduced, greatly enhancing efficacy. Both approaches benefit from the fact the enzymes involved can mediate multiple rounds of prodrug activation greatly amplifying the concentration of active drug generated within the vicinity of a tumor.
ALP was employed in the present study largely as a model therapeutic gene. Nevertheless, despite the fact that most phosphorylated prodrugs such as etoposide phosphate appear to be rapidly converted to their active moieties upon injection, evidence obtained using immunoconjugates suggests that significant therapeutic benefit can still be gained by expressing increased levels of ALP within the tumor microenvironment in vivo. 18, 19 Presumably elevating the level of ALP at the tumor site ensures exposure to a higher concentration of drug than can be achieved as a result of systemic administration.
Whereas splice -activated gene expression can clearly be used to target the expression of essentially any therapeutic gene, one can envisage engineering both phosphatases and/ or phosphorylated prodrugs to further increase specificity such that drug activation occurs only at the site of therapeutic phosphatase expression. 32 Finally, although CD44 was used as an example, there are numerous other genes that appear to be differentially spliced within tumor cells. 33 -44 Incorporation of such alternatively spliced exons into minigene constructs may further expand the potential usefulness of alternative splicing as a novel means of targeting gene expression to tumor cells in vivo.
